

3. DEC. 2003 11:04

K. J. LEUVEN-REGA INSTITUTEN


NO. 971 P. 2

Declaration of Dominique Schols

I, Dominique Schols, declare as follows:

1. I am the sole inventor of the subject matter of claims to methods to use AMD 3100 to treat conditions mediated by CXCR4.
2. I am aware of a publication authored by Donzella *et al.*, *Nature Medicine* 4: 72-77 (January 1998). The publication date of this document was less than one year prior to 8 July 1998, the priority date to which these claims are entitled. This publication has not been cited in the prosecution as a publication that anticipates the present claims.
3. I am the second listed author on this paper. However, all of the work in the paper is conceptually my own and the other co-authors did not contribute to the concept described in the paper that AMD 3100 targets the CXCR4 receptor.
4. Moreover, prior to January 1998, I discovered that AMD 3100 interacts with the chemokine receptor CXCR4, as evidenced by the publications Schols, D. *et al.*, *J. Exp. Med.* 186: 1383-1388 (1997), and Schols, D. *et al.*, *Antiviral Res.* 35: 147-156 (1997). All the work in both publications are conceptually my own, and the co-authors did not contribute to the concept described in the publications that AMD 3100 targets the CXCR4 receptor.
5. I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Executed at LEUVEN, BELGIUM December 2003.  
(City) (State) (Day)

  
Dominique Schols